P&U Launches Cabaser In The UK
Pharmacia & Upjohn has launched Cabaser (cabergoline), its long-actingdopamine agonist for the once-daily treatment of Parkinson's disease, in the UK, its first market for this indication.
The drug is approved for use in combination with levodopa, although it is approved as a stand-alone therapy for early-stage disease in a few markets. Subsequent launches are due to take place within the next few weeks in Denmark and Germany (Marketletter March 24).
The price to the National Health Service will be L3.95 ($6.39) per day. The product comes in packs of 20 tablets (1mg, 2mg and 4mg), and costs L76.00 per pack. The recommended starting dose is 0.5mg-1mg, with a maximum recommended dose of 6mg per day. Most patients are controlled on 4mg per day, said a spokeswoman for the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze